Related Experiment Video

Updated: Jun 28, 2026

An Assay to Detect Protection of the Retinal Vasculature from Diabetes-Related Death in Mice
04:36

An Assay to Detect Protection of the Retinal Vasculature from Diabetes-Related Death in Mice

Published on: January 12, 2024

Sustained moderate visual loss as a predictive end point for visual loss in non-proliferative diabetic retinopathy

A Girach1, L P Aiello, R C Milton

  • 1Department of Ophthalmology, Merck Research Laboratories, Hertfordshire, UK. aniz_girach@merck.com

Eye (London, England)
|November 8, 2008
PubMed
Abstract

Insights

Sustained moderate visual loss (SMVL) is a more reliable predictor of future vision decline in diabetic retinopathy patients than a single instance of moderate visual loss (MVL). This finding impacts how visual loss is measured and predicted in clinical trials.

Area of Science:

  • Ophthalmology
  • Diabetic Retinopathy Research
  • Clinical Trial Endpoints

Background:

  • Diabetic retinopathy is a leading cause of vision loss.
  • Accurate prediction of visual loss is crucial for effective treatment strategies.
  • The PKC-DRS2 trial investigated ruboxistaurin for diabetic retinopathy.

Purpose of the Study:

  • To evaluate if sustained moderate visual loss (SMVL) is a more accurate predictor of future visual loss than moderate visual loss (MVL).
  • To compare the predictive value of SMVL versus MVL in patients with diabetic retinopathy.

Main Methods:

  • Analysis of 869 eyes from 506 patients in the PKC-DRS2 trial over 36 months.
  • Patients had moderately severe to very-severe non-proliferative diabetic retinopathy.
  • Visual acuity was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) chart.

Main Results:

  • Eyes with SMVL onset within 24 months were more likely to have persistent SMVL at 36 months (65%) compared to those with MVL onset (24%).
  • This predictive difference was consistent across various time points (6, 12, 18 months).

Conclusions:

  • Sustained moderate visual loss (SMVL) is a more predictable measure of subsequent visual loss.
  • SMVL offers a more robust endpoint for predicting future vision decline in diabetic retinopathy compared to MVL.

Related Concept Videos

Diabetic Retinopathy01:27

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...